Baxter International Inc (BAX) company profile
Close on Nov 17, 2026Market cap $13.33BP/E –Yield 2.02%
About Baxter International
Surgical & Medical Instruments & Apparatus, SIC 3841
Baxter International Inc. provides essential healthcare products and therapies across three primary operating segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. Its portfolio includes sterile intravenous solutions, infusion systems, parenteral nutrition therapies, surgical sealants and equipment, smart beds, patient monitoring systems, respiratory health devices, specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. These products serve diverse healthcare providers, including hospitals, nursing homes, rehabilitation centers, ambulatory surgical facilities, doctor offices, dialysis centers, and home-care patients.
The company manufactures products in more than 20 countries and sells to healthcare providers in over 100 countries worldwide. Baxter maintains international commercial operations spanning Europe, the Middle East, Africa, Asia-Pacific, Latin America, and Canada, while employing approximately 37,500 people globally across its domestic and foreign locations. In addition, the organization maintains research and development facilities in Belgium, India, Italy, Malta, and the United States, and conducts corporate operations from its headquarters in Deerfield, Illinois.
Summary of the business section of Baxter International's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Baxter International Inc
- Founded
- 1931
- Headquarters
- Deerfield, IL
- Address
- One Baxter Parkway 60015
- Phone
- (224) 948-2000
- Website
- baxter.com
- Employees
- 37,500, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Chicago, Illinois
Stock & identifiers
- Ticker
- BAX
- Exchange
- NYSE
- IPO date
- Oct 27, 1981
- Shares outstanding
- 517M, Oct 22, 2026
- Public float
- $16.00B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 2-for-1, May 31, 2001; 2-for-1, Nov 18, 1983; 2-for-1, Nov 9, 1981
- SEC CIK
- 10456
- CUSIP
- 071813109
- ISIN
- US0718131099
- FIGI
- BBG000BCVJ77
- Share class FIGI
- BBG001S5P1K3
- LEI
- J5OIVXX3P24RJRW5CK77
- EIN
- 36-0781620
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Andrew P. Hider | President and CEO, Director | 518,447 |
| Terence John Rogers | EVP and CFO | 0 |
| Bernard Heine | AVP, Finance InterimCAO&Cntrlr | 32,840 |
| James Teaff | President, CCS | 30,370 |
| Julie Foster | President, Front Line Care | 29,164 |
| Steven P. Wallace | President, Adv. Surgery | 70,128 |
| Anita A. Zielinski | SVP, Interim CFO, CAO & Cntrlr | 59,714 |
| Maria Cecilia Soriano | Group Pres., ITT & Pharma. | 75,045 |
| Joel T. Grade | EVP and CFO | 271,674 |
| David S. Rosenbloom | EVP and General Counsel | 138,216 |
| Reazur Rasul | EVP,Group Pres,Healthcare | 125,557 |
| Cynthia Carlisle | Executive Vice President, CHRO | 0 |
| Jeanne K. Mason | EVP, Chief HR Officer | 199,853 |
| James W. Borzi | EVP,Chief Supply Chain Officer | 71,948 |
| Alok Sonig | EVP,Group President,Pharma | 128,219 |
| Heather Knight | EVP, Chief Operating Officer | 177,362 |
| Christopher A. Toth | EVP, Group Pres, Kidney Care | 105,186 |
| Jose E. Almeida | Chairman, CEO, President | 568,565 |
| Michael R. McDonnell | Director | 14,647 |
| Patricia Morrison | Director | 42,386 |
| Nancy M. Schlichting | Director | 34,994 |
| Jeffrey A. Craig | Director | 23,662 |
| David S. Wilkes | Director | 37,076 |
| David Brent Shafer | Director | 72,804 |
| William A. Ampofo II | Director | 30,375 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr.Almeida | $7.67M | $3.07M | $5.20M | $27 | $148 |
| FY2025 Mr.Hider | $29.81M | $14.72M | $5.20M | $27 | $148 |
| FY2025 Mr.Shafer | $3.81M | $3.29M | $5.20M | $27 | $148 |
| FY2024 | $18.07M | $9.20M | $6.51M | $40 | $129 |
| FY2023 | $13.79M | $10.41M | $5.19M | $51 | $126 |
| FY2022 | $13.59M | -$9.11M | $6.72M | $66 | $124 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| Andrew Hider President and CEO | $499.32K | $1.00M | $23.13M | $3.19M | $820.13K | $1.17M | $29.81M | – |
| José E. Almeida Former Chair of the Board, President and CEO | $660.42K | – | – | – | – | $7.01M | $7.67M | -58% |
| Brent Shafer Non-Executive Chair and Former Executive Chair and Interim CEO | $701.64K | $654.84K | $2.40M | – | – | $52.70K | $3.81M | – |
| Joel Grade Former Executive Vice President and CFO | $827.83K | – | $5.81M | $1.05M | $459.00K | $63.70K | $8.21M | +26% |
| Heather Knight Former Executive Vice President, COO and Interim Group President, Medical Products & Therapies | $747.12K | – | $4.02M | $1.27M | – | $41.80K | $6.07M | -8% |
| Reazur Rasul Executive Vice President and Group President, Healthcare Systems & Technologies | $800.00K | – | $2.95M | $931.51K | $488.00K | $73.29K | $5.25M | – |
| David Rosenbloom Executive Vice President and General Counsel | $760.00K | – | $1.99M | $627.35K | $348.84K | $68.94K | $3.79M | – |
| Alok Sonig Former Executive Vice President and Group President, Pharmaceuticals | $779.75K | – | $3.38M | $1.06M | – | $19.58K | $5.24M | -2% |
| Cecilia Soriano Group President, Infusion Therapies & Technologies and Pharmaceuticals | $668.25K | $75.00K | $1.30M | $253.47K | $291.73K | $66.24K | $2.65M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, after giving effect to the Kidney Care sale, we employed approximately 37,500 people globally, with approximately 15,100 employees in the United States and approximately 22,400 employees outside of the United States.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?